A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study).
EClinicalMedicine
; 55: 101771, 2023 Jan.
Article
in En
| MEDLINE
| ID: mdl-36712888
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Prognostic_studies
Language:
En
Journal:
EClinicalMedicine
Year:
2023
Document type:
Article
Affiliation country:
China